TestDynamics Secures $9M to Expand Imaging AI Evaluation
A hospital's own scans are part of the due diligence TestDynamics sells. That makes clinical validation staff a consequential use of capital for a medical-imaging AI company: the people checking a tool's performance help determine whether the hospital should buy it, keep it or replace it.
The Austin, Texas company announced $9M in funding on November 16, 2026, with its Series A led by Healthier Capital and strategic participation from Cedars-Sinai Technology Ventures. TestDynamics plans to expand clinical validation, reach additional health systems and enter more imaging subspecialties through Satori, its vendor-neutral platform. The announcement puts investment behind a business that helps providers manage the growing choice of imaging algorithms, including the work required to decide which ones belong in a particular clinical setting.
How Satori changes the buying decision
For a hospital, the useful question reaches beyond whether an algorithm performed well in somebody else's demonstration. An imaging leader needs to understand how it behaves on the studies the department actually sees, under local protocols and alongside the people responsible for interpreting the result. Those questions turn evaluation into an operating assignment, with staff time and purchasing consequences attached.
TestDynamics describes Satori Catalogue as a way to match clinical needs with candidate algorithms and test them on the provider's own de-identified studies before commitment. Clinicians and leaders review the evidence, which becomes the baseline for subsequent measurement. The buyer has a role in deciding what success means before the tool becomes part of the department's routine.
The contract structure gives that evaluation a commercial consequence. TestDynamics says it holds contracts and business associate agreements with AI vendors, allowing the provider to work through one agreement. A tool that misses its agreed goals can be replaced under those terms. That arrangement makes the ability to change suppliers part of the initial purchase, rather than leaving the department to negotiate its way out after an algorithm disappoints.
The radiologist still approves the finding
The company's Satori View documentation describes a shared presentation of algorithm findings inside the radiologist's workflow. Results appear as the underlying algorithm produced them, and the radiologist approves what enters the viewer or draft report. Bringing results together therefore carries a specific boundary: the clinical decision remains with the physician reading the study.
Founder and CEO Lior Eshel Ansher and CMO Elie Basse are the named executives on TestDynamics' current team page. Their company's offer combines technical connections with clinical work, giving hospital leaders a counterpart for the choices surrounding deployment. A usable interface matters because another source of findings can also become another demand on a reader's attention.
TestDynamics' Satori Governance description extends that relationship into performance measurement against local goals, recorded feedback and decisions about whether to keep or replace a tool. Its product page presents Governance as new at RSNA 2026, so the described capabilities should be understood as the company's product proposition rather than proof of universal deployment. The practical ambition is to keep the evidence attached to a tool after procurement, when the people responsible for it still need to explain why it remains in use.
Why the Cedars-Sinai relationship matters
Cedars-Sinai's involvement has a history beyond this financing. The institution named TestDynamics to its ninth accelerator class in July 2023, a program offering companies hands-on work with healthcare researchers, administrators and clinicians. That record establishes an earlier institutional connection without requiring an assumption about the size or terms of its current investment.
In a Healthcare Innovation interview reported by David Raths, Lior Eshel Ansher described an early deployment at Cedars-Sinai after the accelerator. The team worked with radiologists and changed the interface in response to their requests. That account supplies a useful view of the work behind an integration: the department's users helped shape how the system reached them.
Healthier Capital leads the Series A, while Cedars-Sinai Technology Ventures participates strategically. Their roles place a healthcare investment firm and a health system's venture operation around the same company. The relationship is relevant because TestDynamics sells into an environment where access to clinical judgment can influence product development. It provides context for the investors' interest, while actual purchasing decisions and subsequent use remain the responsibility of each provider.
What the funding asks the team to scale
The official announcement describes $9M in funding with a Series A led by Healthier Capital. It does not separately reconcile the Series A proceeds with earlier financing, disclose a valuation or provide investor check sizes. Keeping that accounting intact lets the operating plan carry the analysis without inflating the amount of new capital available.
Expansion across hospitals and subspecialties also brings more local evidence to interpret. An algorithm selected for one use case needs evaluation in the next setting, and the people supporting the program must understand the clinical objective before deciding whether the results meet it. The funding plan's emphasis on validation staff recognizes that recurring work alongside software development and deployment.
For an imaging leader, TestDynamics is offering an ongoing relationship around the AI already bought and the tools still to come. The company has chosen to support selection, connection, review and replacement through the same platform. As Satori reaches additional departments, its clinical team will be working through another hospital's scans, another set of agreed goals and another group of radiologists deciding what deserves a place in the report.
Healthcare AI funding, last 30 days
DevCuration's funding database tracked 27 Healthcare AI rounds totaling $1.6B in disclosed capital over the past 30 days. Recent deals we covered:
- Betterness Raises $1M to Expand Miami Wellness NetworksSeed Extension · $1M · Nov 16
- Knit Health Raises $35M Series A for Clinical AI DeploymentSeries A · $35M · Nov 16
- Remedy Robotics Raises $62M Series B for N1 Clinical TrialsSeries B · $62M · Nov 16
- Ellipsis Health Acquires Kouper for AI Care NavigationNov 14
- Kardi Ai Raises Over €5.3M for ECG Monitoring ExpansionSeries A · €5.3M+ · Nov 14
Frequently Asked Questions
How does Satori evaluate an imaging AI tool for a particular hospital?
TestDynamics says candidate tools run on the provider's own de-identified studies before commitment. Clinicians and leaders review the findings, and the chosen tool's results provide a local baseline for later measurement.
Can a hospital replace an imaging algorithm without starting procurement again?
TestDynamics says it holds vendor contracts and brings providers under one agreement. Under its described terms, a tool that misses agreed goals can be replaced through that agreement.
Who decides whether an AI finding enters the radiology report?
The radiologist approves the finding. Satori View displays the underlying algorithm's output unchanged; it does not replace the physician's judgment.
How is Cedars-Sinai connected to TestDynamics?
Cedars-Sinai named TestDynamics to its accelerator class in July 2023. Cedars-Sinai Technology Ventures is also a strategic participant in the financing announced in November 2026.
What work will the announced financing support?
TestDynamics plans to expand its clinical validation team, deploy Satori across additional health systems and extend into more imaging subspecialties. The company has not separately disclosed a reconciliation of the Series A proceeds with its earlier funding.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved

